UAE Bispecific Antibody Market Analysis

UAE Bispecific Antibody Market Executive Summary

UAE Bispecific Antibody Market is valued at around $2.3 Bn in 2022 and is projected to reach $4.4 Bn by 2030, exhibiting a CAGR of 8.2% during the forecast period 2023-2030.

The Bispecific Antibody Market refers to the market for the treatment of diseases like cancer and autoimmune diseases with bispecific antibodies, it features two antigen-binding sites within a single molecule. Bispecific antibodies come in various shapes and sizes, from huge IgG-like molecules with extra domains to small proteins with two linked antigen-binding fragments. The therapeutic success of currently available bispecific antibodies has sped up the development of these antibodies in oncology.

The increasing prevalence of cancer and autoimmune disorders has contributed to the growth of the global market for bispecific antibodies in recent years. According to WHO, there were around 50 Mn cases of autoimmune disorders and cancer was the second leading cause of the death. Advancements and new developments in bispecific antibodies for the treatment of these diseases are driving the market.

There are many companies in the global bispecific antibody market but Roche Holding AG, Amgen Inc., Genentech, Inc., Regeneron Pharmaceuticals, Inc., Merus N.V., Xencor, Inc., Bristol-Myers Squibb Company, Novartis AG, Teneobio, Inc., and MacroGenics, Inc. are some of the major players in the market.

Bispecific Antibodies can be used in the treatment of different diseases, including cancer, autoimmune disorders, and infectious diseases. It plays a crucial role in the development of novel and effective treatments for improving patient outcomes. For example, Blinatumomab is a bispecific antibody that targets CD19 and CD3 has been approved for the treatment of B-cell acute lymphoblastic leukemia, and is also being evaluated for the treatment of hematologic malignancies.

The increasing prevalence of chronic diseases and funding in research and development is projected to fuel the market for bispecific antibodies. The market still has many challenges like high development and commercialization costs, complex regulatory procedures, and immunogenic concerns.

Market Dynamics

Drivers of UAE Bispecific Antibody Market:

Growing Incidence and Prevalence of Chronic Diseases: The prevalence of chronic diseases like cancer, autoimmune disorders, and infectious diseases is increasing with every passing year. It is driving a demand for a more effective and innovative therapeutic approach. Bispecific antibodies have improved treatment outcome and it has the potential to fulfill unmet medical needs. This is raising the demand for the bispecific antibody market.

Advancement in Biotechnology: Technological innovations like antibody engineering and protein modification techniques have enabled the improved therapeutic potential of bispecific antibodies. It has also improved the precise targeting and therapeutic mechanism of bispecific antibodies. This is fueling the demand for the global bispecific antibody market.

Increasing Investment in Research and Development: Around 120 large, mid-sized, and small pharma companies can be found in the research and development of bispecific antibodies. In contrast to the over 180 candidates in the preclinical stages of development, over 220 bispecific antibodies are now either approved or being studied in the clinical stages of development. Additionally, there are many companies that are involved in contract manufacturing and research. Increasing investment in research and development has driven the growth of the market.

Restraints of UAE Bispecific Antibody Market:

Complex Manufacturing Procedure: Bispecific antibodies frequently need complicated production procedures, which can be problematic in terms of product quality consistency, cost-effectiveness, and scalability. The manufacture of bispecific antibodies must be reproducible and robust, so it is important to optimize the manufacturing procedures.

High Cost: The development and production of bispecific antibodies involve a huge amount of investment in research, preclinical and clinical trials, and infrastructure for manufacturing. It can be a restraint for smaller research organizations and biotechnology companies.

Complex Regulatory Procedures: The development and commercialization of bispecific antibodies require different types of regulatory licenses and approval for clinical and preclinical trials. Other types of standards for safety, efficacy, and quality should be followed to complete the regulatory procedures which can be challenging and time-consuming.

Immunogenicity Concerns: Bispecific antibodies can generate immune responses in patients which can lead to safety concerns and reduced efficacy. It can be challenging to manage such incidents and it can cause hurdles to the growth of the bispecific antibody market.

Notable Deals in Bispecific Antibody Market:

In March 2023, Akeso Biopharma declared that enrolment for a phase III trial of the drug Cadonilimab, which is to be used as first-line therapy for advanced gastric or gastroesophageal junction cancer when combined with chemotherapy, has been completed. It is also important to note that the target indications where bispecific antibodies have demonstrated their efficacy have been broadened with the most recent approval of TecvayliTM for the treatment of relapsed or refractory multiple myeloma.